Investor Presentation • Apr 28, 2021
Investor Presentation
Open in ViewerOpens in native device viewer
This presentation and the information contained herein have been prepared by and is the sole responsibility of Protector Forsikring ASA (the "Company"). Such information is being provided to you solely for your information and may not be reproduced, retransmitted, further distributed to any other person or published, in whole or in part, for any purpose. Failure to comply with this restriction may constitute a violation of applicable securities laws. The information and opinions presented herein are based on general information gathered at the time of writing and are therefore subject to change without notice. The Company assumes no obligationsto update or correct any of the information set out herein.
These materials may contain statements about future events and expectations that are forward-looking statements. Any statement in these materials that is not a statement of historical fact including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.
This presentation does not constitute or form part of, and is not prepared or made in connection with, an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purposes whatsoever on the information contained in this presentation or on its completeness, accuracy or fairness. The information in this presentation is subject to verification, completion and change. The contents of this presentation have not been independently verified. While the Company relies on information obtained from sources believed to be reliable, it does not guarantee its accuracy or completeness. Accordingly, no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its owners, directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this presentation. None of the Company, its affiliates or any of their respective advisors or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. The Company's securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), and are offered and sold only outside the United States in accordance with an exemption from registration provided by Regulation S of the US Securities Act.
This presentation should not form the basis of any investment decision. Investors and prospective investors in securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such company and the nature of the securities. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in any offering documents published in relation to such an offering. For further information about the Company, reference is made public disclosures made by the Company, such as filings made with the Oslo Stock Exchange, periodic reports and other materials available on the Company's web pages.


Investor Presentation
Oslo, 29 April 2021

Sverre Bjerkeli Chief Executive Officer
Vision
The Challenger
This will happen through unique relationships, best in class decisionmaking and cost effective solutions
Cost and quality leadership
Profitable growth
Top 3
Credible
Innovative/Open
Bold
Committed




| in MNOK | |||
|---|---|---|---|
| Business unit | Q1 '21 | Q1 '20 Growth | |
| Norway | 856 | 820 | 36 |
| Sweden | 895 | 789 | 106 |
| Denmark | 727 | 813 | - 86 |
| UK | 238 | 192 | 45 |
| Finland | 164 | 213 | - 49 |
| Protector | 2 880 | 2 828 | 52 |
| COI | 47 | 63 | - 16 |
| Protector incl. COI | 2 927 | 2 891 | 36 |

1 Net effect of large losses defined as gross losses or gross absolute loss adjustments > MNOK 10

| Business unit | Q1 '21 Gross |
Q1 '21 Net |
Q1 '20 Gross |
Q1 '20 Net |
|---|---|---|---|---|
| Norway | 68 % | 84 % | 94 % | 96 % |
| Sweden | 61 % | 65 % | 80 % | 79 % |
| Denmark | 104 % | 84 % | 105 % | 113 % |
| UK | 75 % | 83 % | 66 % | 80 % |
| Finland | 102 % | 98 % | 68 % | 69 % |
| Protector | 75 % | 79 % | 86 % | 90 % |

• Gross large losses of MNOK 27, or 1.9% in Q1
• Volatility must be expected



1 Large losses defined as gross losses or gross absolute loss adjustments > MNOK 10 2 Two very large claims capped at MNOK 100
| Norway | Sweden | Denmark | UK | Finland | Protector | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2021 | Q1 2020 | Q1 2021 | Q1 2020 | Q1 2021 | Q1 2020 | Q1 2021 | Q1 2020 | Q1 2021 | Q1 2020 | Q1 2021 | Q1 2020 | |
| Gross premium written | 856 | 820 | 895 | 789 | 727 | 813 | 238 | 192 | 164 | 213 | 2 880 | 2 828 |
| Gross premium earned | 343 | 367 | 434 | 397 | 207 | 234 | 334 | 227 | 70 | 68 | 1 388 | 1 293 |
| Net premium earned | 305 | 328 | 373 | 349 | 180 | 204 | 254 | 181 | 62 | 61 | 1 175 | 1 122 |
| Gross claims ratio | 68.1 % | 94.3 % | 61.1 % | 80.3 % | 103.6 % | 105.0 % | 75.2 % | 65.7 % | 101.6 % | 67.6 % | 74.6 % | 85.5 % |
| Gross cost ratio | 8.9 % | 7.6 % | 14.7 % | 12.1 % | 10.4 % | 5.7 % | 18.5 % | 12.4 % | 8.2 % | 3.9 % | 13.2 % | 9.3 % |
| Gross combined ratio | 77.0 % | 101.9 % | 75.7 % | 92.3 % | 114.0 % | 110.8 % | 93.7 % | 78.1 % | 109.8 % | 71.5 % | 87.8 % | 94.8 % |
| Net claims ratio | 83.7 % | 96.1 % | 65.1 % | 78.8 % | 84.1 % | 112.7 % | 83.2 % | 80.1 % | 98.3 % | 69.0 % | 78.5 % | 89.7 % |
| Net cost ratio | 10.5 % | 4.8 % | 13.3 % | 11.3 % | 6.5 % | 8.3 % | 19.0 % | 13.5 % | 9.2 % | 1.0 % | 12.6 % | 8.6 % |
| Net combined ratio | 94.2 % | 100.8 % | 78.4 % | 90.1 % | 90.6 % | 121.0 % | 102.2 % | 93.5 % | 107.5 % | 70.0 % | 91.1 % | 98.3 % |
• Quarterly volatility on country level must be expected.



Gross vs. net CR: "Darag result effect in Q1 '21" of MNOK -53.8. GWP effect of WC exit of MNOK 31. Underlying growth and profitability looks good. Price increases on EB products still necessary.
Good figures. New sales stronger than anticipated and will probably continue going forward. Some price increases still necessary on Property products.

Price increases on Motor still necessary. "Money sent to reinsurers". Small volume quarter and low new sales, also slowing down going forward.
GWP effect of WC exit of MNOK 159 – now history. Renewal rate on a high level on all other products.
Covid-19 continues to influence growth negatively, but UK is gradually opening up now.
No critical mass – small figures – high volatility
Accumulated Darag effect is close to zero on company level; in line with expectations
Gross vs. net CR: "Darag result effect in Q1 '21" of MNOK 53.9.


| Guiding 2021 | Result Q1 | Status | |
|---|---|---|---|
| Net Combined Ratio: | 90-92% | 91.1% | Ahead |
| Return on Equity (ROE): | >20% | 17.5%* | Ahead |
| Gross Written Premium (GWP) growth: | 10% (LCY) | 1.5% (LCY) | Behind |
| Solvency II Capital Ratio (SCR): | > 150% | 216% | Very solid |



Investment is core



• Remember that we invest for the long run; quarterly gains or losses will to a great extent be unrealized.

| Portfolio data | 31.03.21 | 31.12.20 | 31.03.20 |
|---|---|---|---|
| Size bond & cash eq. (MNOK)1 |
12 472 | 11 603 | 10 151 |
| Avg. ref. rate (NIBOR, STIBOR, etc.) |
0.1% | 0.2% | 0.5% |
| Avg. spread/risk premium (bps) |
179 | 210 | 320 |
| Yield | 2.0% | 2.3% | 2.1% |
| Duration | 0.4 | 0.4 | 0.4 |
| Credit duration2 | 1.4 | 1.4 | 2.2 |
| Avg. rating3 |
A- | A- | A |
1 Size excludes forward foreign currency contracts
2Avg. includes bank deposits
3Avg. based on official rating (>60%) and 'Protector rating' (<40%) & is based on linear rating (as usual). WARF methodology would give a somewhat lower IG-rating

1Avg. based on official rating (>60%) and 'Protector rating' (<40%) & is based on linear rating (as usual). WARF methodology would give a somewhat lower IG-rating


Vision
The Challenger
This will happen through unique relationships, best in class decisionmaking and cost effective solutions
Cost and quality leadership
Profitable growth
Top 3
Credible
Innovative/Open
Bold
Committed
| NOKm | Q1 2021 | Q1 2020 | FY 2020 |
|---|---|---|---|
| Gross premiums written | 2880.2 | 2 828.0 | 5 516.3 |
| Gross premiums earned | 1 387.9 | 1 293.2 | 5 379.6 |
| Gross claims incurred | (1 035.2) | (1 105.8) | (4 424.6) |
| Earned premiums. net of reinsurance | 1 175.2 | 1 122.3 | 4 613.5 |
| Other insurance related income | 2.9 | 4.2 | 19.5 |
| Claims incurred, net of reinsurance | (922.8) | (1 006.4) | (3 901.4) |
| Sales cost | (101.5) | (71.7) | (331.3) |
| Administration cost | (81.8) | (48.3) | (221.3) |
| Commission from reinsurer | 35.6 | 23.0 | 81.6 |
| Other insurance related income/expenses | (12.8) | (0.1) | 5.5 |
| Technical result | 92.0 | 18.8 | 246.6 |
| Other income/costs | (17.2) | (16.3) | (67.0) |
| Net financial income | 523.0 | (322.8) | 865.2 |
| Profit before tax | 597.8 | (320.3) | 1 044.8 |
| ax | (71.0) | 39.7 | (160.0) |
| Discontinued operations | 50.6 | (114.7) | 94.3 |
| Net comprehensive income | (4.7) | 10.4 | 2.4 |
| Profit for the period | 572.8 | (384.9) | 981.6 |
| Claims ratio, net of reinsurance | 78.5 % | 89.7 % | 84.6 % |
| Expense ratio. net of reinsurance | 12.6 % | 8.6 % | 10.2 % |
| Combined ratio, net of reinsurance | 91.1 % | 98.3 % | 94.8 % |
| Gross claims ratio | 74.6 % | 85.5 % | 82.2% |
| Gross expense ratio | 13.2 % | 9.3 % | 10.3 % |
| Gross combined ratio | 87.8 % | 94.8 % | 92.5 % |
| Retention rate | 84.7 % | 86.8 % | 85.8 % |
| Earnings per share | 7.0 | (4.8) | 12.0 |
• GWP growth at 1.8% (1.5% in LCY)
4% return on investments; 27.2% on equities and 0.7% on fixed income securities
3.3%-points lower than net CR; meaning money "is sent" to reinsurers

| In millions | 31.03.2021 | 31.03.2020 | 31.12.2020 |
|---|---|---|---|
| Owner-occupied property | 0.0 | 12.7 | 0.0 |
| Financial assets | 13 400.5 | 10 337.6 | 11 988.6 |
| Derivatives | 73.0 | 300.9 | 47.9 |
| Bank deposits | 165.5 | 182.9 | 263.2 |
| Other assets | 4 495.1 | 3 480.4 | 2 554.9 |
| Discontinued operations |
1 876.4 | 2 301.9 | 1 895.7 |
| Total assets | 20 010.5 | 16 616.4 | 16 750.3 |
| Total equity | 3 584.5 | 1 630.4 | 3 030.5 |
| Subordinated loan capital | 1 472.9 | 1 243.3 | 1 473.0 |
| Total reserves | 10 520.2 | 10 662.0 | 9 185.1 |
| Derivatives | 59.7 | 150.6 | 61.4 |
| Other liabilities | 3 349.4 | 1 414.4 | 1 888.7 |
| Discontinued operations | 1 023.7 | 1 515.7 | 1 111.6 |
| Total equity and liabilities | 20 010.5 | 16 616.4 | 16 750.3 |
• Change in SCR-ratio driven by WC Darag-deal, investment result and improved technical profitability
17

SCR-ratio composition


SCR composition
18


Main capital allocation alternatives:
1
2
5

| • Determine minimum hurdle rate (RoE>20%) |
|
|---|---|
| Capital allocation approach | • Calculate returns for all internal and external allocation alternatives available, by return and risk |
| • Deploy capital in the most attractive alternatives above hurdle. |
|
| • Release underperforming capital (COI, Price increases, WC Denmark and Norway as example) |
|

| 180% 150% |
Current level = 216%* |
• Capital over 180% in SCR ratio distributed over time |
||
|---|---|---|---|---|
| Normal Range | • Shareholder distribution normally 20%-80% of net profit • Quarterly decisions, all allocation alternatives evaluated • Profitable insurance growth always prioritized |
|||
| • Build solvency capital, any shareholder distribution only after a careful consideration |






(1)Claims ratio, net of reinsurance (2)Expense ratio, net of reinsurance (3)Combined ratio, net of reinsurance (4)Gross claims ratio (5)Gross expense ratio (6)Gross combined ratio (7)Retention rate (8)Earning per share
(1)Claims incurred in % of earned premiums, net of reinsurance
(2)Operating expenses in % of earned premiums, net of reinsurance
(3)Net claims ratio + net expense ratio
(4)Gross claims incurred in % of gross premiums earned
(5)Sales and administration costs in % of gross premiums earned
(6)Gross claims ratio + gross expense ratio
(7)Earned premiums, net of reinsurance in % of gross earned premiums
(8)Profit before other comprehensive income divided by weighted number of shares

Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.